Log in to save to my catalogue

NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in mye...

NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in mye...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4529359

NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

Publication information

Publisher

New York: Nature Publishing Group US

More information

Scope and Contents

Contents

Carl June and colleagues report the results of a phase I/II trial of adoptively transferred engineered T cells in patients with advanced multiple myeloma.
Despite recent therapeutic advances, multiple myeloma (MM) remains largely incurable. Here we report results of a phase I/II trial to evaluate the safety and activity of autologous T cells eng...

Alternative Titles

Full title

NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4529359

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4529359

Other Identifiers

ISSN

1078-8956

E-ISSN

1546-170X

DOI

10.1038/nm.3910

How to access this item